SOSV is an accelerator and a global venture capital firm that focuses on investing around four key verticals: hardware, biotechnology & biodesign, food, and China/Asia internet and e-commerce. The firm operates four accelerator programs that provide funding, mentoring and training in these areas: HAX, Chinaccelerator, Food-X Accelerator and IndieBio. HAX is an accelerator that specializes in the hardware, manufacturing, startups, product development, positioning, marketing and prototyping sectors. Chinaccelerator is the longest running accelerator in China (2010), based in Shanghai, and investing in companies focused on internet and e-commerce platforms for the China/Asia market. FOOD-X is focused on launching food-related ventures, located in New York. IndieBio focuses on entrepreneurs building technologies in or around the fields of biotechnology, biodesign and synthetic biology, offering seed funding and lab space as well as mentorship to start-ups, located in San Francisco and Cork, Ireland.
Dr. Jenny Rooke has been deploying capital at the frontiers of life sciences innovation, with a penchant for technology-fueled solutions and category-defying opportunities. Jenny got her start in venture at Fidelity Biosciences, a Cambridge-based healthcare VC, during their Fund I formation. Jenny then brought her unique toolkit of genetics domain expertise, strategic business acumen, and venture investing to the Gates Foundation, where she deployed and managed over $250M in funding in genetic engineering, diagnostics, and synthetic biology. She also played a key role in establishing the foundation’s investing function. In 2014, Dr. Rooke began independently investing under the brand 5 Prime Ventures, financing her investments using what has become the largest life sciences syndicate on AngelList, and one of the highest-performing AngelList syndicates of any sector. Jenny founded Genoa Ventures in 2018, building on the 5 Prime Ventures track record, in order to scale a proven, differentiated investing strategy, to ensure continued access to the very best deals, and to maximize portfolio returns.